GlassScriptPhysician profile
Brian F Canavan
NPI 1760595516
$3,145.53
in general payments reported to CMS, 2019-2025
55 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $182 · 2021: $25.79 · 2022: $533 · 2023: $987 · 2024: $680 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785 · Education: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.09 |
| Education | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $222.03 | 2019-2023 | Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $191.47 | 2019-2024 | Enhertu, Injectafer |
| Karyopharm Therapeutics INC. | $150.01 | 2020-2023 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $138.02 | 2023 | Opdivo, Opdualag |
| Blueprint Medicines Corporation | $135.10 | 2023-2024 | Ayvakit |
| Seagen INC. | $130.43 | 2019-2023 | Padcev |
| Exelixis INC. | $128.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $126.22 | 2019-2024 | |
| Epizyme, INC. | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.79 | 2019-2024 | |
| Genentech USA, INC. | $100.47 | 2019-2024 | Venclexta, Polivy, Lunsumio |
| Pfizer INC. | $98.25 | 2019-2024 | |
| Abbvie INC. | $94.09 | 2019-2025 | Venclexta |
| Genzyme Corporation | $89.64 | 2019-2023 | |
| Astellas Pharma US INC | $78.43 | 2023-2024 | Xtandi, Xospata, Padcev |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Canavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.